Myovant Sciences Ltd.

FREE EMAIL WATCHDOG

Get free email notifications about news in Myovant Sciences Ltd..

The service is free and you can unsubscribe at any time.

General | People (37) | Filings (90) | Annual reports (1) | Stock | News

Industry: PHARMACEUTICAL PREPARATIONS [2834]

CIK Number: 0001679082

Myovant Sciences Ltd. is a publicly traded company

Trading symbol: MYOV

News

2017-11-16

Myovant Sciences (MYOV) & Its Peers Head-To-Head Survey
Dispatch Tribunal
Myovant Sciences logo Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders.

2017-11-16

Myovant Sciences Ltd. (MYOV) Stock Rating Reaffirmed by Cowen and Company
StockNewsTimes
Myovant Sciences Ltd. (NYSE:MYOV)'s stock had its “buy” rating reissued by equities research analysts at Cowen and Company in a research note issued on Tuesday.
Myovant Sciences Ltd. (MYOV) Given Buy Rating at Cowen and Company - TrueBlueTribune

2017-11-14

Brokerages Set Myovant Sciences Ltd (MYOV) Price Target at $20.00
Dispatch Tribunal
Myovant Sciences logo Myovant Sciences Ltd (NASDAQ:MYOV) has earned an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports.
Cowen and Company Reaffirms Buy Rating for Myovant Sciences Ltd (MYOV) - Week Herald
Myovant Sciences Ltd - Receive News & Ratings Daily - BBNS

2017-11-13

Myovant Sciences Provides Corporate Update and Reports Financial Results for ...
PR Newswire (press release)
13, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced corporate updates and reported ...
25100 Shares in Myovant Sciences Ltd (MYOV) Acquired by Swiss National Bank - Dispatch Tribunal
Placing the Money Flow Index Under Scrutiny For Myovant Sciences Ltd (MYOV) - Rockville Register

2017-11-12

Myovant Sciences Ltd (MYOV) Given Buy Rating at Robert W. Baird
TrueBlueTribune
Myovant Sciences Ltd logo Robert W. Baird reaffirmed their buy rating on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report released on Friday morning.
Myovant Sciences Ltd (MYOV) Rating Reiterated by Robert W. Baird - Week Herald

2017-11-11

Myovant Sciences Ltd. Shares See a Change of -4.53% This Week
Concord Register
Myovant Sciences Ltd. (:MYOV) shares saw the needle move -4.53% on the week. The stock closed the most recent session at $14.21 after seeing 14510 shares trade hands.
Robert W. Baird Reaffirms Buy Rating for Myovant Sciences Ltd (MYOV) - The Ledger Gazette
Myovant Sciences (MYOV) Earning Somewhat Favorable Media Coverage, Accern Reports - Week Herald

2017-11-09

Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 ...
PR Newswire (press release)
BASEL, Switzerland, Nov. 9, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Takeda Pharmaceutical Company Limited ...

Myovant Sciences Ltd. address

20-22 BEDFORD ROW
LONDON
WC1R 4JS

Earliest known filing

July 2016

Latest known filing

November 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

Myovant Sciences Ltd. has 90 filings. View Myovant Sciences Ltd. filings.

Annual Reports

Quarterly Reports

Latest company events

People

We have found 37 people related to Myovant Sciences Ltd..